ArticleAnnals of clinical microbiology and antimicrobials2017
Evaluation of lytic bacteriophages for control of multidrug-resistant Salmonella Typhimurium.
Article in Annals of clinical microbiology and antimicrobials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 57 citations in OpenAlex.
- A novel phage encoding host defense modulators demonstrates in-vivo therapeutic efficacy against carbapenem-resistant E. coli ST1432.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Salmonellosis as a One Health-One Biofilm Challenge: Biofilm Formation byPharmaceuticals (Basel, Switzerland) · 2025Review
- Isolation and characterization of bacteriophages with lytic activity against multidrug-resistant non-typhoidal Salmonella from Nairobi City county, Kenya.BMC infectious diseases · 2025Article
- Alternatives to antibiotics for sustainable livestock production in the context of the One Health approach: tackling a common foe.Frontiers in veterinary science · 2025Review
- Advancements in Detection Methods forPathogens (Basel, Switzerland) · 2024Review
- Mini review advantages and limitations of lytic phages compared with chemical antibiotics to combat bacterial infections.Heliyon · 2024Review
- A novel lytic phage infecting MDRFrontiers in microbiology · 2024Article
- Identification of a lytic bacteriophage against clinical isolates ofVeterinary research forum : an international quarterly journal · 2024Article
- Evaluation of the Lytic Activity of Various Phage Cocktails Against, ESBL-Producer, Non-Producer and Carbapenem-ResistantIndian journal of microbiology · 2023Article
- Bacteriophages: The promising therapeutic approach for enhancing ciprofloxacin efficacy against bacterial infection.Journal of clinical laboratory analysis · 2023Review
- Application of a novel lyticFrontiers in microbiology · 2023Article
- Pathogen genomics and phage-based solutions for accurately identifying and controllingFrontiers in microbiology · 2023Article
- Selection and characterization of bacteriophages specific toVeterinary world · 2022Article
- Article
- A novel lytic phage potentially effective for phage therapy against Burkholderia pseudomallei in the tropics.Infectious diseases of poverty · 2022Article
- Antibiotic resistant bacteria: A bibliometric review of literature.Frontiers in public health · 2022Review
- Isolation and Characterization of PotentialFrontiers in microbiology · 2021Article
- Article
- Exploring the feasibility ofJournal of animal science and technology · 2020Article
- Phage therapy for severe bacterial infections: a narrative review.The Medical journal of Australia · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe emergence of antibiotic-resistant bacteria can cause serious clinical and public health problems. This study describes the possibility of using bacteriophages as an alternative agent to control multidrug-resistant Salmonella Typhimurium.
methodsThe potential lytic bacteriophages (P22-B1, P22, PBST10, PBST13, PBST32, and PBST 35) were characterized by morphological property, heat and pH stability, optimum multiplicity of infection (MOI), and lytic activity against S. Typhimurium KCCM 40253, S. Typhimurium ATCC 19585, ciprofloxacin-induced antibiotic-resistant S. Typhimurium ATCC 19585, and S. Typhimurium CCARM 8009.
resultsP22-B1 and P22 belong to Podoviridae family and PBST10, PBST13, PBST32, and PBST 35 show a typical structure with polyhedral head and long tail, belonging to Siphoviridae family. Salmonella bacteriophages were highly stable at the temperatures (< 60 °C) and pHs (5.0-11.0). The reduction rates of host cells were increased at the MOI-dependent manner, showing the highest reduction rate at MOI of 10. The host cells were most effectively reduced by P22, while P22-B1 showed the least lytic activity. The ciprofloxacin-induced antibiotic-resistant S. Typhimurium ATCC 19585, and clinically isolated antibiotic-resistant S. Typhimurium CCARM 8009 were resistant to ciprofloxacin, levofloxacin, norfloxacin, and tetracycline. P22 showed the highest lytic activity against S. Typhimurium KCCM 40253 (> 5 log reduction), followed by S. Typhimurium ATCC 19585 (4 log reduction) and ciprofloxacin-induced antibiotic-resistant S. Typhimurium ATCC 19585 (4 log reduction).
conclusionThe results would provide vital insights into the application of lytic bacteriophages as an alternative therapeutics for the control of multidrug-resistant pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.